Clinical trials: Depression / Major Depressive Disorder
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).
- Trial name
- NCT01571453
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine extended release
- Volunteers
- 437 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder With Anxious Distress
A Study of JNJ-61393215 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a 17-item Hamilton Depression Rating Scale…
- Trial name
- NCT04080752
- Testing
- JNJ-61393215
- Where
- 35 sites in United States, Moldova and 3 more
- Volunteers
- 222 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Major Depressive Disorder
Trial of Levomilnacipran in Geriatric Depression
The purpose of this study is to examine the effects of levomilnacipran (FETZIMA) compared to placebo for the treatment of depression in older adults.
- Trial name
- LMIL (NCT02466958)
- Testing
- levomilnacipran
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of California, Los Angeles
Depressive Disorder, Major, Cannabis Abuse
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
Adolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major…
- Trial name
- CADY (NCT00149643)
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram
The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers.
- Trial name
- NCT00851006
- Testing
- Creatine Monohydrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Utah
Major Depressive Disorder, Dysthymic Disorder
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
The goal of this open-administration treatment study of citalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of "frailty" in older adults with depressive symptoms.
- Conditions
- Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
- Trial name
- NCT01973283
- Testing
- Antidepressant Medication
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major…
- Trial name
- NCT00388973
- Testing
- Quetiapine
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
The purpose of this study is to learn how to help veterans play a stronger role in shaping their mental health care. Specifically we want to see if we can help veterans improve their mental health treatment by helping them decide…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression
- Trial name
- NCT00466323
- Testing
- Family Member Provider Outreach, Enhanced treatment as usual (e-TAU)
- Where
- 2 sites in United States
- Volunteers
- 238 people
- Sponsor
- US Department of Veterans Affairs
Major Depressive Disorder (MDD)
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
This is an 8-week, randomized, double blind, parallel group, 3-arm trial to compare 10 mg/day, 20 mg/day and 40 mg/day as starting doses of vilazodone following a switch from generic SSRIs and SNRIs.
- Trial name
- NCT02015546
- Testing
- Vilazodone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Duke University
Depression, Depressive Disorder, Major
An Expert System to Reduce Depression in Primary Care
The purpose of this study is to determine whether a home-based intervention matched to stage of change (readiness) for using effective methods to prevent or reduce depression can improve depression outcomes in primary care.
- Trial name
- NCT00497874
- Testing
- Computer-tailored intervention
- Where
- 2 sites in United States
- Volunteers
- 902 people
- Sponsor
- Pro-Change Behavior Systems
Major Depressive Disorder, Suicidal Ideation
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
The study aims to use a combined clinical and translational approach to identify an efficient pharmacotherapy for the acute management of suicidality and the epigenetic regulation associated with the treatment.The primary…
- Trial name
- AFSP (NCT01134731)
- Testing
- paliperidone, lithium
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Alabama at Birmingham
Depressive Disorder, Depression
Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode
- Trial name
- NCT03288714
- Testing
- Synchronized Transcranial Magnetic Stimulation (sTMS)
- Where
- 14 sites in United States
- Volunteers
- 121 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder, Insomnia
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult participants with comorbid major depressive disorder (MDD) and insomnia.
- Trial name
- NCT03771664
- Testing
- SAGE-217
- Where
- 28 sites in United States
- Volunteers
- 87 people
- Sponsor
- Biogen
Adjunctive Treatment of Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with…
- Trial name
- NCT03018340
- Testing
- Pimavanserin
- Where
- 36 sites in United States
- Volunteers
- 207 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Postpartum Depression
Postpartum Depression: Transdermal Estradiol Versus Sertraline
The purpose of this study is to determine whether estrogen patches are effective for the treatment of postpartum major depression, as compared to sertraline (Zoloft) and placebo.
- Trial name
- E2SERT (NCT00744328)
- Testing
- Transdermal Estradiol, Sertraline
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Northwestern University
Depression - Major Depressive Disorder
Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)
To determine the bioequivalence of 2 tablets of 25 mg sustained release (SR) formulation of DVS and 1 tablet of 50 mg SR formulation of DVS under fed and fast conditions.
- Trial name
- NCT01190514
- Testing
- desvenlafaxine succinate sustained release
- Where
- Belgium
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
In this Phase 4 trial we will study the safety, tolerability and efficacy of mixed salts amphetamine (MSA), trade name Adderall, augmentation of antidepressant therapy for Major Depressive Disorder (MDD) in depressed outpatient…
- Trial name
- NCT02058693
- Testing
- mixed salts amphetamine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rush University Medical Center